Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/08/2023* -- Results Q4 2022 -- 1.07 --
02/08/2023* 10:00 EST Earnings Call Q4 2022 -- -- --
11/01/2022 -- Results Q3 2022 1.78 1.40 27.03%
11/01/2022 10:00 EST Earnings Call Q3 2022 -- -- --
07/28/2022 10:00 EST Earnings Call Q2 2022 -- -- --
07/28/2022 -- Results Q2 2022 2.04 1.78 14.80%
05/03/2022 -- Results Q1 2022 1.62 1.57 3.47%
05/03/2022 10:00 EST Earnings Call Q1 2022 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 02/08/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/01/2022
Beat/Miss Upgrade
Return Since 6.95%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
URL https://www.pfizer.com
Investor Relations URL https://investors.pfizer.com
HQ State/Province New York
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Feb. 08, 2023 (est.)
Last Earnings Release Nov. 01, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Nov. 03, 2022

Dividends

Dividend Per Share (TTM) 1.59
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.432
Yield to Sector 2.100
Yield to Industry 1.006
Last Dividend Amt. 0.40
Dividend Frequency Quarterly
Last Ex-Dividend Date Nov. 03, 2022
Yield (TTM) 3.17%
Forward Yield 3.14%
Payout Ratio 29.99%
Cash Payout Ratio 38.21%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-11.00%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
--
--
--
--
28.09%
434.1%
143.1%
-28.20%
3.97%
-7.55%
22.25%
15.17%
27.62%
-2.00%
0.87%
30.91%
1.16%
15.32%
24.40%
-5.14%
16.21%
10.85%
11.45%
7.31%
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
37.51%
As of December 02, 2022.

Profile

Edit
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
URL https://www.pfizer.com
Investor Relations URL https://investors.pfizer.com
HQ State/Province New York
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Feb. 08, 2023 (est.)
Last Earnings Release Nov. 01, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Nov. 03, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
XLV 2.349B USD 5.44%
CWMFX 3.383B USD 2.49%
RIDAX 2.648B USD 2.42%
VTV 2.315B USD 1.55%
CLBFX 2.650B USD 1.47%
IVV 2.605B USD 0.83%
SPY 3.171B USD 0.83%
FXAIX 2.653B USD 0.81%
VFINX 5.978B USD 0.80%
VOO 5.978B USD 0.80%
VTSMX 7.841B USD 0.68%
VTI 7.841B USD 0.68%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter PFE Tweets